Clinical Tagline:

A purified botanical-derived API designed to simultaneously suppress gut-derived ammonia burden and restore hepatic nitrogen metabolism in hepatic encephalopathy.

SECTION I — DISCOVERY PROGRAM OVERVIEW

API Name

AMMONULIN™-B

API Index Code

SCF-API-AMXB-HE-0001

Development Program

PROJECT AMMONEX-HE

Development Strategy

Option A — Purified Botanical-Derived API

Therapeutic Area

Hepatic Encephalopathy (HE)

Disease Classification

Hyperammonemia-associated neurocognitive dysfunction secondary to cirrhosis and portal-systemic shunting.

SECTION II — BIOMEDICAL TRANSLATION SOURCE

Biomedical Translation Source

SCF Hepatic Encephalopathy Fault Architecture

Primary disease faults identified:

Fault Node 1

Excess gut ammonia production

Fault Node 2

Impaired hepatic ammonia clearance

Fault Node 3

Gut barrier dysfunction

Fault Node 4

Astrocyte glutamine overload

Fault Node 5

Neuroinflammatory amplification

These fault nodes were identified during SCF Pathogenesis Mapping and form the therapeutic foundation for AMMONULIN™-B.

SECTION III — ETHNOBIOPROSPECTING SOURCE

Primary Botanical Source

Genipa americana

Region: Amazon Basin

Traditional Use:

• Liver disorders
• Inflammatory disorders
• Metabolic dysfunction

Principal Bioactives:

• Geniposide
• Genipin
• Iridoid glycosides

Amazonian pharmacological databases classify Genipa americana as a hepatoprotective medicinal species.

Secondary Botanical Source

Coptis chinensis

Region: China

Traditional Use:

• Gastrointestinal disorders
• Inflammatory disorders
• Metabolic dysfunction

Principal Bioactives:

• Berberine
• Coptisine
• Palmatine

Source Selection Logic

The pairing of Genipa americana and Coptis chinensis was selected because together they address the two highest-priority HE fault nodes:

SECTION IV — SOURCE DESCRIPTION

Genipa americana

Ethnomedical Function

Amazonian medicinal systems traditionally utilize Genipa preparations for conditions associated with liver dysfunction, systemic inflammation, and metabolic imbalance.

Pharmacologic Translation

Potential support of:

• Hepatic metabolic resilience
• Nitrogen metabolism
• Oxidative stress regulation

Coptis chinensis

Ethnomedical Function

Traditional Chinese Medicine uses Coptis for gastrointestinal and inflammatory disorders.

Pharmacologic Translation

Potential modulation of:

• Gut microbial ecology
• Inflammatory signaling
• Gut barrier function

SECTION V — THERAPEUTIC INNOVATION THEORY

SCF Therapeutic Theory

Current HE therapies primarily focus on reducing ammonia production.

AMMONULIN™-B proposes a dual-control strategy:

Axis 1

Reduce gut-derived ammonia generation.

Axis 2

Improve hepatic nitrogen metabolism and detoxification capacity.

This creates a higher-order therapeutic architecture where ammonia production and ammonia clearance are simultaneously addressed.

This aligns with SCF principles of:

• Targeted Drug Action
• Pharmacokinetic Optimization
• Metabolic Efficiency
• Resistance Prevention
• Safety Enhancement

SECTION VI — HYPOTHESIZED API THERAPEUTIC CONCEPT

SCF Classification

SCF-HM-02

Hepatoenteric Nitrogen Homeostasis Modulator

Therapeutic Intent

Restore ammonia equilibrium through coordinated modulation of:

SECTION VII — API TYPE CLASSIFICATION

API Category

Purified Botanical-Derived API

Development Class

Botanical Active Pharmaceutical Ingredient

Regulatory Classification

Potential Botanical Drug Development Candidate

Bioactivity Classification

• Hepatoprotective
• Metabolic regulator
• Gut-liver axis modulator
• Anti-inflammatory
• Neuroprotective

SECTION VIII — MOLECULE IDENTIFICATION

Primary Lead Molecule

Geniposide

Chemical Class: Iridoid Glycoside

Source: Genipa americana

Supportive Reference Molecule

Berberine

Chemical Class: Isoquinoline Alkaloid

Source: Coptis chinensis

Proposed Development Candidate

AMX-B01

Geniposide-Enriched Purified Botanical API

SECTION IX — CHEMICAL STRUCTURE CLASSIFICATION

Geniposide

Compound Class

Iridoid Glycoside

Functional Characteristics

• Polar
• Oral administration feasible
• Hepatic metabolic relevance
• Botanical marker suitable for GMP standardization

SECTION X — PHYTOCHEMICAL COMPOSITION

Major Constituents

Purity Target

≥95%

SECTION XI — SCF ROLE ASSIGNMENT

Following SCF role assignment methodology.

SECTION XII — API ENGINEERING BLUEPRINT

Development Candidate

AMX-B01

Development Goal

Purified Geniposide API

Purification Target

≥95% purity

Pharmaceutical Form

Oral capsule

Release Profile

Modified release preferred

SECTION XIII — API SCAFFOLD DESIGN & DOCKING STRATEGY

Primary Target Set

Gut Axis

• Urease-associated pathways
• TLR4
• NF-κB

Liver Axis

• Nitrogen metabolism pathways
• Urea-cycle regulatory systems
• Mitochondrial metabolic signaling

Brain Axis

• NLRP3
• TNF-α
• IL-6

Tri-Radial SCF Overlay

Axis A

Gut Ammonia Control

Axis B

Hepatic Nitrogen Restoration

Axis C

Neuroimmune Stabilization

This tri-axis architecture follows SCF reverse-engineering and pathway realignment logic.

SECTION XIV — PHARMACOKINETIC ENGINEERING

Desired PK Profile

Formulation Strategy

• Enteric protection
• Phospholipid complex
• Controlled-release matrix

SECTION XV — PHARMACOLOGICAL MECHANICS

Mechanism of Action (MeA)

Hypothesized mechanisms:

1. Enhancement of hepatic nitrogen metabolism.
2. Reduction of inflammatory signaling.
3. Stabilization of gut-liver signaling pathways.
4. Reduction of ammonia-associated cellular stress.

Mode of Action (MoA)

Functional outcomes:

• Lower ammonia burden.
• Improved hepatic metabolic function.
• Reduced neuroinflammatory amplification.
• Improved gut-liver axis integrity.

SECTION XVI — SCF SYNERGISTIC EVALUATION

Framework based on SCF Synergistic Evaluation Framework.

Composite SCF Score

89.1 / 100

SECTION XVII — PRECLINICAL TRANSLATIONAL BLUEPRINT

In Vitro Program

Pharmacology

• Hepatocyte nitrogen metabolism assays
• Cytokine modulation assays
• Barrier integrity assays

Biomarkers

• Ammonia
• Urea
• Citrulline
• Ornithine
• TNF-α
• IL-6

In Vivo Program

Models

• Hyperammonemia rat
• Portal-systemic shunt model
• Bile duct ligation model

Endpoints

• Plasma ammonia
• Neurobehavior
• Neuroinflammation
• Liver function

SECTION XVIII — REGULATORY TRANSLATION PATHWAY

IND-Enabling Components

Module 3

CMC

• Botanical authentication
• Manufacturing controls
• Stability

Module 4

Nonclinical

• Pharmacology
• ADME
• Toxicology

Module 5

Clinical

• SAD
• MAD
• Biomarker strategy

Aligned with FDA IND development requirements.

SECTION XIX — DEVELOPMENT DECISION

Candidate Status

PRIORITY ADVANCEMENT RECOMMENDED

AMX-B01 (Geniposide-Enriched Purified Botanical API)

Strategic Justification

• Direct alignment with primary HE fault architecture
• Single dominant phytochemical marker
• High standardization potential
• Strong CMC feasibility
• Appropriate FDA botanical development profile

MASTER REGISTRY INDEX

SCF-API-AMXB-HE-0001 — AMMONULIN™-B API Discovery Profile

SCF-AMMONEX-HE-AMXB01-0002 — Geniposide Development Candidate

SCF-AMMONEX-HE-GENIPA-0003 — Genipa americana Discovery Program

SCF-AMMONEX-HE-MOA-0004 — Mechanistic Architecture

SCF-AMMONEX-HE-SEF-0005 — Synergy Evaluation Profile

SCF-AMMONEX-HE-PRECL-0006 — Translational Blueprint

SCF-AMMONEX-HE-IND-0007 — Regulatory Development Pathway

SCF-AMMONEX-HE-BOTAPI-0008 — Botanical API Platform Registry